Ove Juul Nielsen

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without <i>NPM1</i> Mutations

Sylvie Freeman, Robert K. Hills, Paul Virgo et al. · Journal of Clinical Oncology · 2018 · 200 citations · Full text

Medicine, Hematology, Oncology +17

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Sif Gudbrandsdottir, Henrik Birgens, Henrik Frederiksen et al. · Blood · 2013 · 174 citations · Full text

Life Sciences, Hematology, Immunology +7

A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy <i>versus</i> glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia

Henrik Birgens, Henrik Frederiksen, Hans Carl Hasselbalch et al. · British Journal of Haematology · 2013 · 173 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area

Morten Krogh Jensen, Peter de Nully Brown, Ove Juul Nielsen et al. · European Journal Of Haematology · 2000 · 141 citations · Full text

Medicine, Hematology, Internal Medicine +11

Risk group assignment differs for children and adults 1–45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL‐2008 protocol

Nina Toft, Henrik Birgens, Jonas Abrahamsson et al. · European Journal Of Haematology · 2013 · 138 citations

Medicine, Oncology, Pediatrics +6